Replies to post #306062 on Avid Bioservices Inc (CDMO)

[peregr]

Bio-SoCal is a very interconnected biotech community and is how Ronin knows of Peregrine. My greatest concern is the Tustin criminal cabal makes it so difficult with their control of the nominating process, that Ronin says this is so messed up, we walk. Then we all lose. Big Time. Add 10 more years to your landscaping career to continue to pay the Board annuity. Vote Ronin in, and you can start thinking about your early retirement years. You want to see outrage, wait until the cabal comes out with a response letter. It will be so full of disinformation, you will be trying to connect the puzzle pieces for years.

[swg_tdr]

biopharm, good work - for once the pieces connect to our "near future"

thanks
N

[biopharm]

Saiid ties to Ambit and Intrexon (Peregrine direct ties shown ...

Part II

Ok after too many yellow stickies ..no sleep.. and a little reorg....we are back on a path that reinforces why Ronin MUST file for ALL collaborations (past present future) and with Dr Jedd Wolchok speaking out supporting PS Targeting... there is NO WAY I want anyone making a deal for shareholders unless all collaborations are revealed that may force all shareholders to stand up to Ronin and ask WHY do they seem biased against the science of PS Targeting? Why?!

So if you review the prior post we show Ronin candidate for BOD => Saiid had the ties to Ambit (which I have been harping on for many months to find out the extent of Peregrine's involvement re: CS1FR
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=103209171

..so now let's move over to Intrexon:

CEO Billionaire Randal J Kirk
https://en.m.wikipedia.org/wiki/Randal_J._Kirk

Board member of
Intrexon Corporation (since 2008)
Halozyme Therapeutics (since 2007)
ZIOPHARM Oncology (since 2011)


Maria Karasarides

July 2014

from BMS/Inifinty/Merrimack/Ziopharm to AZ
Maria Karasarides, Ph.D. - just added

Experience

Sr. Director, ImmunoOncology, Global Medicines Development
AstraZeneca
July 2014 – Present (1 year 5 months)

Executive Director, Clinical Development
Ziopharm Oncology
September 2013 – June 2014 (10 months)Boston, MA

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118290095

--------------------------

Dr David Page ...also research ties to Ziopharm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129118504

------------------------

My oh my...lots of Memorial Sloan Kettering ties to Ziopharm including Dr Jedd Wolchok

http://www.ziopharm.com/about/board-of-directors
http://www.ziopharm.com/about/management-team
http://www.ziopharm.com/about/medical-advisory-board

Through a collaboration with Intrexon, ZIOPHARM intends to expand ..
http://www.ziopharm.com/pipeline

Intrexon
https://www.dna.com/Company/Board-of-Directors

Well too many connections so we save them for part III and anyone read Peregrine Stephen Worsley profile lately? Maybe Intrexon was in his past, present...and future

Let's go Ronin....go public and request ALL Peregrine collaborations and only then you may give PS Targeting the credit it deserves vs the foolishness of stopping RD activity with Dr Jedd Wolchok (who is with Ziopharm as well...)

Should be enough puzzle pieces for you all ...for now

[north40000]

Would PS targeting be useful or helpful to LJPC in its oncology efforts/trials? I recall 1 of 3 Ronin nominees has/had a very direct relationship with LJPC.